【文獻(xiàn)精讀】超聲和MRI測(cè)量的硬膜外間隙深度與腰椎硬膜外類固醇注射時(shí)臨床阻力消失的相關(guān)性
Luffy帶你讀文獻(xiàn)
Correlation between epidural space depth measured with ultrasound and MRI compared to clinical loss of resistance when performing lumbar epidural steroid injection
超聲和MRI測(cè)量的硬膜外間隙深度與腰椎硬膜外類固醇注射時(shí)臨床阻力消失的相關(guān)性
前 言
Background This prospective study assessed the accuracy of MRI and ultrasound (US) measurements as a preprocedural assessment tool for predicting clinical loss of resistance depth (CLORD) during fluoroscopy-guided lumbar epidural steroid injections (ESIs).
本前瞻性研究評(píng)估了MRI和超聲(US)測(cè)量作為預(yù)測(cè)透視引導(dǎo)下腰椎硬膜外類固醇注射(ESIs)過程中臨床穿刺阻力消失深度(CLORD)的術(shù)前評(píng)估工具的準(zhǔn)確性。
Materials and methods Sixty patients enrolled received lumbar ESIs at an academic chronic pain clinic.
60例患者在慢性疼痛門診接受腰椎穿刺治療。
The MRI measurement calculated the distance between the skin and the posterior epidural space, while US measurements included transverse and parasagittal oblique views of the interlaminar space. The epidural space measurements were compared with the CLORD during the performance of the prone epidural injections.
MRI測(cè)量計(jì)算皮膚與后硬膜外間隙之間的距離,而US測(cè)量包括層間間隙的橫向和矢狀斜位視圖。將俯臥位硬膜外注射時(shí)的硬膜外間隙測(cè)量與CLORD進(jìn)行比較。
Results MRI was equivalent to CLORD with a mean difference of –0.2 cm (95%CI –0.39 to –0.11). US transverse and US parasagittal oblique measurements were not equivalent to and underestimated CLORD with mean differences of –0.98 cm (90%CI –1.8 to –0.77) and –0.79 cm (90% CI −1.0 to −5.9), respectively. The intraclass correlation coefficients between MRI and CLORD were the highest at 0.85, compared with 0.65 and 0.73 for transverse and parasagittal oblique US views, respectively.
MRI與CLORD相當(dāng),平均差值為-0.2 cm (95%CI -0.39 ~ -0.11)。US橫向和US副矢狀面斜向測(cè)量不等于或低估了CLORD,平均差異分別為-0.98 cm (90%CI -1.8至-0.77)和-0.79 cm (90%CI - 1.0至- 5.9)。MRI與CLORD之間的類內(nèi)相關(guān)系數(shù)最高,為0.85,而橫向和副矢狀面斜位US分別為0.65和0.73。
Conclusions MRI measurements are preferable over US for preprocedural assessment of patients receiving lumbar ESIs for predicting CLORD.
結(jié)論 MRI測(cè)量在術(shù)前評(píng)估腰椎ESIs患者預(yù)測(cè)CLORD方面優(yōu)于US。
結(jié) 果
1.US measurements and MRI measurements.
硬膜外間隙橫向(左)和斜矢狀旁(右)測(cè)量。橫切面顯示棘間韌帶(ISL)。鞘內(nèi)間隙☆周圍可見后椎體(PVB)和橫突(TP)。黃韌帶(LF)也用測(cè)量線末端的x表示。在矢狀旁斜位面,L4和L5椎板在L4-5間隙清晰可見。
腰椎MRI矢狀位T2圖像(右)顯示L4-L5水平(右)從皮膚表面到硬膜外間隙后側(cè)的測(cè)量。
2.CLORD needle measurements臨床穿刺阻力消失時(shí),穿刺針的深度測(cè)量
The average depth in MRI was 6.46±1.48cm, and the CLORD was 6.66±1.72cm. In comparison, transverse and parasagittal oblique US views averaged 5.68±1.3cm and 5.86±1.28cm, respectively (table 1).
MRI平均深度為6.46±1.48cm, CLORD為6.66±1.72cm。相比之下,橫切面和副矢狀面斜位US片平均分別為5.68±1.3cm和5.86±1.28cm(表1)。
3.Equivalency tests between imaging measurements and CLORD
成像測(cè)量與CLORD之間的等效性測(cè)試
MRI was found to be equivalent to CLORD with a mean difference of −0.2cm (90% CI –0.39 to –0.01, TOST p value =0.005) (table 2). US transverse and parasagittal oblique views were not found to be equivalent to CLORD (p values both =0.99), with mean differences of −0.98cm (90%CI −1.2 to –0.77) and −0.79cm (90% CI −1.0 to –0.59), respectively (table 2). Using a Bonferroni correction for the three tests, the significance cutoff becomes alpha =0.017, and the difference between MRI and CLORD remains significant.
MRI發(fā)現(xiàn)與CLORD相當(dāng),平均差值為- 0.2cm (90%CI -0.39至-0.01,TOST p值=0.005)(表2)。US橫切面和副矢狀面斜位視圖未發(fā)現(xiàn)與CLORD相當(dāng)(p值均=0.99),平均差值分別為- 0.98cm (90%CI - 1.2至-0.77)和- 0.79cm (90%CI - 1.0至-0.59)(表2)。對(duì)三個(gè)測(cè)試使用Bonferroni校正,顯著性截止值為α =0.017。MRI和CLORD之間的差異仍然顯著。
4.The difference between the imaging modalities and CLORD did not significantly vary with age and sex. However, for those with a BMI of 30 or greater, the difference between CLORD and US parasagittal oblique was 1.29 (0.92) compared with 0.46 (0.87) for those with BMI lower than 30 (p value <0.001). Similarly, the difference in the CLORD and US transverse view measurements was 1.47 (0.92) for the higher BMI group compared with 0.61 (0.83) for the lower BMI group (p value <0.001).
成像方式和CLORD之間的差異在年齡和性別上沒有顯著差異。然而,對(duì)于BMI為30或更高的患者,CLORD和US旁矢狀斜位的差異為1.29(0.92),而BMI低于30的患者為0.46 (0.87)(p值<0.001)。同樣,高BMI組的CLORD和US橫斷面測(cè)量值的差異為1.47(0.92),而低BMI組的差異為0.61 (0.83)(p值<0.001)
總 結(jié)
本研究分析了CLORD(硬膜外穿刺過程中阻力消失時(shí)的穿刺深度)與超聲和MRI腰椎硬膜外深度測(cè)量的相關(guān)性。研究發(fā)現(xiàn)US和MRI測(cè)量與clod相關(guān)。然而,MRI在預(yù)測(cè)皮膚與后硬膜外間隙之間的距離方面似乎比US更準(zhǔn)確。腰椎ESIs(硬膜外類固醇注射)應(yīng)用,MRI比US預(yù)測(cè)CLORD更具有等效性、一致性和相關(guān)性。
原文標(biāo)題 : 【文獻(xiàn)精讀】超聲和MRI測(cè)量的硬膜外間隙深度與腰椎硬膜外類固醇注射時(shí)臨床阻力消失的相關(guān)性

發(fā)表評(píng)論
請(qǐng)輸入評(píng)論內(nèi)容...
請(qǐng)輸入評(píng)論/評(píng)論長(zhǎng)度6~500個(gè)字
圖片新聞
-
ChatZOC,藏在口袋里的「眼科醫(yī)生」
-
金百澤科技亮相中國(guó)國(guó)際醫(yī)療器械博覽會(huì) | 盡顯醫(yī)療領(lǐng)域硬實(shí)力
-
進(jìn)階的新冠疫苗 又一個(gè)中國(guó)造
-
“AI醫(yī)療第一股”鷹瞳科技上市首日即破發(fā)
-
圓心科技登陸港股,“賣藥的生意”還好不好做?
-
十圖解讀2021年中國(guó)康復(fù)醫(yī)療行業(yè)現(xiàn)狀
-
醫(yī)藥流通數(shù)字化運(yùn)營(yíng)實(shí)現(xiàn)精細(xì)化飼養(yǎng)
-
科學(xué)家發(fā)現(xiàn)人體新器官:將有助于癌癥治療
技術(shù)文庫(kù)
最新活動(dòng)更多
-
7.30-8.1火熱報(bào)名中>> 全數(shù)會(huì)2025(第六屆)機(jī)器人及智能工廠展
-
7月30-31日報(bào)名參會(huì)>>> 全數(shù)會(huì)2025中國(guó)激光產(chǎn)業(yè)高質(zhì)量發(fā)展峰會(huì)
-
8月5日立即報(bào)名>> 【在線會(huì)議】CAE優(yōu)化設(shè)計(jì):醫(yī)療器械設(shè)計(jì)的應(yīng)用案例與方案解析
-
精彩回顧立即查看>> 【線下論壇】新唐科技2025新品發(fā)布會(huì)
-
精彩回顧立即查看>> 【在線會(huì)議】研華嵌入式核心優(yōu)勢(shì),以Edge AI驅(qū)動(dòng)機(jī)器視覺升級(jí)
-
精彩回顧立即查看>> OFweek 2025(第十四屆)中國(guó)機(jī)器人產(chǎn)業(yè)大會(huì)
- 1 中國(guó)疫苗,邁入新周期
- 2 起底“神藥”艾本那肽
- 3 2025 ADA前瞻:中國(guó)創(chuàng)新藥的“破圈”與“突圍”(附摘要匯總)
- 4 港股創(chuàng)新藥走出至暗時(shí)刻
- 5 250美元的代價(jià):諾和諾德減肥神藥提前痛失專利保護(hù)
- 6 腫瘤微環(huán)境在癌癥中的發(fā)展變化
- 7 多股大漲,醫(yī)藥行業(yè)的商業(yè)變現(xiàn)周期走到哪了?
- 8 誰(shuí)是下一個(gè)三生制藥?
- 9 癌癥治療中的耐藥困局:從機(jī)制解析到破局之道
- 10 國(guó)產(chǎn)創(chuàng)新藥迎來密集收獲期,這些藥企值得關(guān)注!